Table 3 Fine-Gray multivariable analysis for locoregional and distant failure outcomes
Locoregional Failure | Distant Failure | |||||
|---|---|---|---|---|---|---|
aHR | 95% CI | P | aHR | 95% CI | P | |
Cisplatin | ||||||
> / = 5 Cycles | Reference | Reference | ||||
< 5 Cycles | 1.61 | 0.46–5.58 | 0.46 | 4.55 | 1.19–17.3 | 0.03 |
Gender | ||||||
Male | Reference | Reference | ||||
Female | 0.12 | 0.02–0.73 | 0.02 | < 0.001 | < 0.001- < 0.001 | < 0.001 |
Smoker | ||||||
Never | Reference | Reference | ||||
Former | 6.38 | 0.24–170.72 | 0.27 | 5.69 | 0.57–57.1 | 0.14 |
Current | 0.78 | 0.04–14.22 | 0.87 | 3.34 | 0.34–32.9 | 0.3 |
Age | ||||||
< 65 | Reference | Reference | ||||
65 or older | 0.49 | 0.07–3.34 | 0.46 | 0.14 | 0.02–0.88 | 0.04 |
KPS | ||||||
90–100 | Reference | Reference | ||||
< 90 | 1.81 | 0.55–6.00 | 0.33 | 1.74 | 0.23–13.3 | 0.59 |
Race | ||||||
White | Reference | Reference | ||||
Other | 4.78 | 0.69–32.93 | 0.11 | 0.14 | 0.02–0.78 | 0.03 |
BMI | ||||||
Normal | Reference | Reference | ||||
Underweight | 64.4 | 7.90–524.98 | < 0.001 | < 0.001 | < 0.001–0.001 | < 0.001 |
Overweight | 2.6 | 0.63–10.77 | 0.19 | 23 | 2.54–208 | 0.005 |
Obese | 2.04 | 0.48–8.76 | 0.34 | 12.1 | 1.31–113 | 0.03 |
Not available | 0.003 | < 0.001–0.40 | 0.02 | < 0.001 | < 0.001–0.02 | < 0.001 |
Site | ||||||
Oropharynx | Reference | Reference | ||||
Larynx | 0.98 | 0.15–6.52 | 0.99 | 2.75 | 0.27–28.2 | 0.39 |
Oral cavity | < 0.001 | < 0.001–0.12 | 0.01 | 1500 | 22.2–1.01e5 | < 0.001 |
Other | 1.53 | 0.20–11.87 | 0.68 | 1.78 | 0.15–20.8 | 0.65 |
T staging | ||||||
1–2 | Reference | Reference | ||||
3–4 | 18.7 | 1.80–194.53 | 0.01 | 5.33 | 1.20–23.7 | 0.03 |
N staging | ||||||
0–1 | Reference | Reference | ||||
2–3 | 2.34 | 0.28–20.00 | 0.44 | 19.7 | 3.64–106 | < 0.001 |
HPV | ||||||
Negative | Reference | Reference | ||||
Positive | 2.18 | 0.13–36.41 | 0.59 | 1.1 | 0.20–5.95 | 0.91 |
Not available | 5.39 | 0.33–88.75 | 0.24 | 0.5 | 0.07–3.57 | 0.49 |